Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8WXS8

UPID:
ATS14_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8WXS8; Q5T4G0; Q5T4G1; Q8TE55; Q8TEY8

BACKGROUND:
ADAMTS14 is integral to collagen maturation and extracellular matrix stability, through its aminoprocollagen type I processing activity and cleavage of lysyl oxidase LOX. This enzyme is initially produced in a latent form and requires activation to function, highlighting its regulated role in tissue remodeling and development.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ADAMTS14 offers a promising avenue for developing novel therapeutic approaches, especially for conditions associated with abnormal collagen processing and extracellular matrix anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.